Literature DB >> 10611875

Revision arthroplasty of the acetabulum with restoration of bone stock.

A E Gross1.   

Abstract

Bone defects on the acetabular side are defined as contained (cavitary) and uncontained (segmental). Contained (cavitary) defects can be treated by morselized allograft bone with an uncemented cup if contact can be made with 50% host bone. If contact cannot be made with 50% host bone, the author prefers to use a ring and a cemented cup. Defining success as a stable implant, no additional surgery, and improvement in hip score of at least 20 points, the success rate was 90% in 51 hips in 51 patients at an average followup of 7 years. Segmental defects involving between 30% and 50% of the acetabulum are treated by minor column allografts (shelf graft), and a cemented or an uncemented cup. In 29 hips in 28 patients with an average followup of 7 years the success rate was 86%. Segmental defects involving more than 50% of the acetabulum are treated by major column allografts. These grafts are fixed by cancellous screws and protected by a reconstruction ring that extends from ilium to ischium. In 33 hips in 32 patients with an average followup of 7 years, the success rate was 76%.

Entities:  

Mesh:

Year:  1999        PMID: 10611875     DOI: 10.1097/00003086-199912000-00021

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  18 in total

1.  A review of the treatment of pelvic discontinuity.

Authors:  M Villanueva; A Rios-Luna; J Pereiro De Lamo; H Fahandez-Saddi; M P G Böstrom
Journal:  HSS J       Date:  2008-07-15

2.  Late fracture of a Burch-Schneider acetabular cage: rare occurrence following polyethylene cup wear.

Authors:  Dario Regis; Andrea Sandri; Alessandra Rizzo; Pietro Bartolozzi
Journal:  BMJ Case Rep       Date:  2009-03-26

3.  Continued good results with modular trabecular metal augments for acetabular defects in hip arthroplasty at 7 to 11 years.

Authors:  Michael R Whitehouse; Bassam A Masri; Clive P Duncan; Donald S Garbuz
Journal:  Clin Orthop Relat Res       Date:  2015-02       Impact factor: 4.176

4.  Are custom triflange acetabular components effective for reconstruction of catastrophic bone loss?

Authors:  Carl C Berasi; Keith R Berend; Joanne B Adams; Erin L Ruh; Adolph V Lombardi
Journal:  Clin Orthop Relat Res       Date:  2015-02       Impact factor: 4.176

5.  Use of porous tantalum components in Paprosky two and three acetabular revision. A minimum five-year follow-up of fifty one hips.

Authors:  Xavier Flecher; Benjamin Appy; Sébastien Parratte; Matthieu Ollivier; Jean-Noel Argenson
Journal:  Int Orthop       Date:  2016-10-21       Impact factor: 3.075

6.  [Structural femoral head allografts in revision surgery of loosened acetabular cups].

Authors:  C Wedemeyer; S Otte; M von Knoch; U Quint; F von Knoch; F Löer; G Saxler
Journal:  Unfallchirurg       Date:  2007-02       Impact factor: 1.000

7.  The use of customized cages in revision total hip arthroplasty for Paprosky type III acetabular bone defects.

Authors:  Yuanqing Mao; Chen Xu; Jiawei Xu; Huiwu Li; Fengxiang Liu; Degang Yu; Zhenan Zhu
Journal:  Int Orthop       Date:  2015-08-19       Impact factor: 3.075

8.  Results of the cementless Plasmacup in revision total hip arthroplasty: a retrospective study of 72 cases with an average follow-up of eight years.

Authors:  Stefan Lakemeier; Guenter Aurand; Nina Timmesfeld; Thomas J Heyse; Susanne Fuchs-Winkelmann; Markus D Schofer
Journal:  BMC Musculoskelet Disord       Date:  2010-05-27       Impact factor: 2.362

9.  Modular tantalum augments for acetabular defects in revision hip arthroplasty.

Authors:  Alexander Siegmeth; Clive P Duncan; Bassam A Masri; Winston Y Kim; Donald S Garbuz
Journal:  Clin Orthop Relat Res       Date:  2008-10-16       Impact factor: 4.176

10.  Salvage of failed acetabular cages by nonbuttressed trabecular metal cups.

Authors:  Yona Kosashvili; Oleg Safir; David Backstein; Dror Lakstein; Allan E Gross
Journal:  Clin Orthop Relat Res       Date:  2009-06-20       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.